Decision Diagnostics Corp. DECN

DECN Company Overview

Decision Diagnostics Corp. (OTC: DECN) was a healthcare and diagnostics company focused on low-cost medical testing products, primarily in the diabetes monitoring and point-of-care diagnostics markets. The company operated through subsidiaries including PharmaTech Solutions, Inc. and marketed blood glucose testing systems, disposable glucose test strips, and related diabetic supplies intended for retail and consumer healthcare channels. Public disclosures and OTC market materials indicate that the company sought to compete primarily on pricing and compatibility with existing glucose meter platforms.

The company evolved from a small diagnostics and intellectual property-focused business into a developer and marketer of diabetic testing products targeting both U.S. and international markets. During the COVID-19 pandemic, Decision Diagnostics publicly promoted development efforts related to rapid coronavirus testing technologies, although several claims made during that period became the subject of regulatory scrutiny. Publicly available information indicates that trading in the company’s securities was suspended by the U.S. Securities and Exchange Commission in 2020, and subsequent public reporting activity became limited. Data regarding the company’s current operating status is inconclusive based on available public sources.